Upadacitinib Clinical Trials

3 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Also known as: ABT-494, ATC 200000041628, RINVOQ, Rinvoq

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

Universidade do Porto1
NYU Langone Health1
AbbVie1

Indications

Arthritis3
Rheumatic Disease1
Adverse Drug Reaction1
Drug Side Effect1
Juvenile Idiopathic Arthritis1

Other1 trial

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

Phoenix, Arizona1 trial

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Phoenix Children's Hospital /ID# 253403

Phase 3

New York, New York1 trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NYU Langone Health

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.